Login to Your Account

Pregnancy test: Nora's $18M series B will fund miscarriage phase II bid

By Randy Osborne
Staff Writer

Friday, April 18, 2014

In stealth mode until about six months ago, Nora Therapeutics Inc. raised $18 million in series B cash to expand the development of NT100 into a second phase II trial in women with unexplained recurrent loss of pregnancy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription